Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정혜경 | - |
dc.date.accessioned | 2019-04-19T16:30:01Z | - |
dc.date.available | 2019-04-19T16:30:01Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.issn | 1365-2036 | - |
dc.identifier.other | OAK-24572 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/249652 | - |
dc.description.abstract | Background Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. Aim To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE). Methods In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed EE confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms, safety and tolerability were also assessed. Results The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively. Both doses of tegoprazan were non-inferior to esomeprazole 40 mg. The incidence of adverse events was comparable among the groups, and tegoprazan was well-tolerated. Conclusion Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg. | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.title | Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis | - |
dc.type | Article | - |
dc.relation.issue | 7 | - |
dc.relation.volume | 49 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 864 | - |
dc.relation.lastpage | 872 | - |
dc.relation.journaltitle | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.identifier.doi | 10.1111/apt.15185 | - |
dc.identifier.wosid | WOS:000461070100003 | - |
dc.author.google | Lee, Kwang Jae | - |
dc.author.google | Son, Byoung Kwan | - |
dc.author.google | Kim, Gwang Ha | - |
dc.author.google | Jung, Hye-Kyung | - |
dc.author.google | Jung, Hwoon-Yong | - |
dc.author.google | Chung, Il-Kwun | - |
dc.author.google | Sung, In-Kyung | - |
dc.author.google | Kim, Jin Il | - |
dc.author.google | Kim, Jong Hyeok | - |
dc.author.google | Lee, Joon Seong | - |
dc.author.google | Kwon, Joong Goo | - |
dc.author.google | Park, Jung Ho | - |
dc.author.google | Huh, Kyu Chan | - |
dc.author.google | Park, Kyung Sik | - |
dc.author.google | Park, Moo-In | - |
dc.author.google | Kim, Nayoung | - |
dc.author.google | Lee, Oh Young | - |
dc.author.google | Jee, Sam Ryong | - |
dc.author.google | Lee, Sang Kil | - |
dc.author.google | Youn, Sei Jin | - |
dc.author.google | Kim, Sung Kook | - |
dc.author.google | Lee, Soo Teik | - |
dc.author.google | Hong, Su Jin | - |
dc.author.google | Choi, Suck Chei | - |
dc.author.google | Kim, Tae Nyeun | - |
dc.author.google | Youn, Young Hoon | - |
dc.author.google | Park, Hyo Ju | - |
dc.author.google | Kang, Min Ja | - |
dc.author.google | Park, Chi Hye | - |
dc.author.google | Kim, Bong Tae | - |
dc.author.google | Youn, Sangjun | - |
dc.author.google | Song, Geun Seog | - |
dc.author.google | Rhee, Poong-Lyul | - |
dc.contributor.scopusid | 정혜경(7403029723) | - |
dc.date.modifydate | 20230208112902 | - |